Eldorado Hotel & Spa Floorplan
This meeting took place in 2017
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Antimicrobials and Resistance: Opportunities and Challenges (T4)
Organizer(s) Gautam Dantas and Jennifer A. Leeds
October 29—November 1, 2017
Eldorado Hotel & Spa • Santa Fe, NM USA
Discounted Abstract Deadline: Jun 27, 2017
Abstract Deadline: Jul 27, 2017
Scholarship Deadline: Jun 27, 2017
Discounted Registration Deadline: Aug 29, 2017
Supported by the Directors' Fund
Summary of Meeting:
Antimicrobial-resistant (AMR) infections claim numerous lives around the globe annually. This problem is exacerbated by a steady increase in global antimicrobial use and abuse in the clinic and agriculture, and a dearth of novel antimicrobials making it to market. If these scenarios continue unchecked, AMR will cumulatively cost the global economy around 100 trillion dollars by 2050. This conference focuses on the latest work understanding and combatting AMR, including clinical perspectives on AMR diagnostics and management, translational academic perspectives on design of drug regimens and combinations that suppress AMR, pharma perspectives on recent successes and failures in novel antimicrobial development and clinical trials and basic science perspectives on the ecology and transmission of evolving AMR determinants. While these stakeholders are similarly motivated to identify and develop therapies to treat the exceptional, unmet medical need of worsening AMR, their spheres rarely overlap at scientific conferences, leading to communication barriers between subject matter experts. This conference attempts to address this challenge by engaging diverse global perspectives on these topics, including speakers and attendees from academic research, industrial drug development, and healthcare practice and policy.
View Scholarships/Awards
Antimicrobial-resistant (AMR) infections claim numerous lives around the globe annually. This problem is exacerbated by a steady increase in global antimicrobial use and abuse in the clinic and agriculture, and a dearth of novel antimicrobials making it to market. If these scenarios continue unchecked, AMR will cumulatively cost the global economy around 100 trillion dollars by 2050. This conference focuses on the latest work understanding and combatting AMR, including clinical perspectives on AMR diagnostics and management, translational academic perspectives on design of drug regimens and combinations that suppress AMR, pharma perspectives on recent successes and failures in novel antimicrobial development and clinical trials and basic science perspectives on the ecology and transmission of evolving AMR determinants. While these stakeholders are similarly motivated to identify and develop therapies to treat the exceptional, unmet medical need of worsening AMR, their spheres rarely overlap at scientific conferences, leading to communication barriers between subject matter experts. This conference attempts to address this challenge by engaging diverse global perspectives on these topics, including speakers and attendees from academic research, industrial drug development, and healthcare practice and policy.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, October 29 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, November 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, November 2 in order to fully experience the meeting.
SUNDAY, OCTOBER 29
MONDAY, OCTOBER 30
TUESDAY, OCTOBER 31
WEDNESDAY, NOVEMBER 1
THURSDAY, NOVEMBER 2
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, October 29 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, November 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, November 2 in order to fully experience the meeting.
SUNDAY, OCTOBER 29
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:30—09:30
Welcome and Keynote Address
*
Gautam Dantas,
Washington University School of Medicine, USA
Session Chair
Session Chair
Ramanan Laxminarayan,
Center for Disease Dynamics, Economics and Policy, India
Antimicrobial Resistance: Managing a Shared Global Resource
Antimicrobial Resistance: Managing a Shared Global Resource
09:30—12:00
Surveillance and Treatment of Resistant Bacterial Infections in Clinical Practice
*
Gavin Barlow,
Hull and East Yorkshire Hospitals NHS Trust and University of York, UK
Session Chair
Session Chair
Michael J. Satlin,
Weill Cornell Medicine, USA
Clinical Challenges in Treating Patients with Multidrug-Resistant Bacterial Infections
Clinical Challenges in Treating Patients with Multidrug-Resistant Bacterial Infections
Coffee Break
Carey-Ann D. Burnham,
Washington University School of Medicine, USA
Next-Generation Diagnostics: Translating Rapid Pathogen and Resistance Detection to Optimal Antibiotic Prescription
Next-Generation Diagnostics: Translating Rapid Pathogen and Resistance Detection to Optimal Antibiotic Prescription
Calvin Brown,
University of California, Los Angeles, USA
Short Talk: Automated Diagnosis of Antimicrobial Resistance Using a Mobile Phone-Based Well-Plate Reader
Short Talk: Automated Diagnosis of Antimicrobial Resistance Using a Mobile Phone-Based Well-Plate Reader
Jean Patel,
Centers for Disease Control and Prevention, USA
Combatting Antibiotic-Resistant Bacteria: CDC's Implementation of the National Action Plan
Combatting Antibiotic-Resistant Bacteria: CDC's Implementation of the National Action Plan
George A. Cortina,
University of Virginia, USA
Short Talk: Predicting Allosteric Mutations that Increase Esbl-Mediated Antibiotic Resistance
Short Talk: Predicting Allosteric Mutations that Increase Esbl-Mediated Antibiotic Resistance
14:30—16:30
Workshop 1: Novel Therapeutic Strategies
*
Jennifer A. Leeds,
Novartis Institutes for BioMedical Research, USA
Session Chair
Session Chair
Elizabeth Culp,
Yale University, USA
Activation of a Cryptic Glycopeptide Antibiotic-Related Biosynthetic Gene Cluster
Activation of a Cryptic Glycopeptide Antibiotic-Related Biosynthetic Gene Cluster
Nagakumar Bharatham,
BUGWORKS Research India Private Ltd, India
Discovery of a Novel Class of Anti-Bacterial Agents through an Efflux Mitigation Strategy
Discovery of a Novel Class of Anti-Bacterial Agents through an Efflux Mitigation Strategy
Alicia Eve Ballok,
Massachusetts General Hospital, USA
Small Molecule Inhibitors of the MvfR Quorum Sensing Pathway Reduce Neutrophil Recruitment and Cytotoxicity of Pseudomonas aeruginosa in Mono and Polymicrobial Lung Infection Models
Small Molecule Inhibitors of the MvfR Quorum Sensing Pathway Reduce Neutrophil Recruitment and Cytotoxicity of Pseudomonas aeruginosa in Mono and Polymicrobial Lung Infection Models
Sarah L. Keasey,
United States Army Medical Research Institute of Infectious Diseases, USA
Drug-Specific Tolerance Mechanisms within the Proteome of the Persistence Phenotype
Drug-Specific Tolerance Mechanisms within the Proteome of the Persistence Phenotype
Liz Sockett,
University of Nottingham, UK
Predatory Bacteria: “Living Antibiotics” to Treat Antibiotic-Resistant Gram-Negative Infections
Predatory Bacteria: “Living Antibiotics” to Treat Antibiotic-Resistant Gram-Negative Infections
Jade Bojkovic,
NGM Biopharmaceuticals, USA
Mining the Human Microbiome for Novel Antimicrobials
Mining the Human Microbiome for Novel Antimicrobials
Marvin J. Miller,
University of Notre Dame, USA
Syntheses and Studies of Novel Monobactams and other beta-Lactams with Activity Against Gram-Negative Bacteria, including Carbapenemase-Producing Acinetobacter baumannii
Syntheses and Studies of Novel Monobactams and other beta-Lactams with Activity Against Gram-Negative Bacteria, including Carbapenemase-Producing Acinetobacter baumannii
17:00—19:00
Fate and Lessons Learned from Recent Drug Development Programs Focused on Resistant Pathogens or Narrow-Spectrum Agents
*
Richa Chandra,
Novartis Pharmaceuticals, USA
Session Chair
Session Chair
Lorraine D. Hernandez,
Merck Research Laboratories, USA
Monoclonal Antibody Therapy for the Prevention of Recurrent Clostridium difficile Infections
Monoclonal Antibody Therapy for the Prevention of Recurrent Clostridium difficile Infections
Christopher B. Ford,
Seres Therapeutics, USA
Short Talk: Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile infection (CDI)
Short Talk: Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile infection (CDI)
Lynn E. Connolly,
Achaogen, USA
Late-Stage Drug Development: Lessons Learned from Running Resistant Pathogen Focused Clinical Trials
Late-Stage Drug Development: Lessons Learned from Running Resistant Pathogen Focused Clinical Trials
Paul G. Ambrose,
Institute for Clinical Pharmacodynamics, USA
The Future is Combination Antimicrobial Therapy: The Question is a Combination of What?
The Future is Combination Antimicrobial Therapy: The Question is a Combination of What?
08:30—11:30
Alternative Approaches to Tackling Resistant Infections
*
Matthew Henn,
Seres Therapeutics, USA
Session Chair
Session Chair
Helen I. Zgurskaya,
University of Oklahoma, USA
Synergistic Interplays between Active Drug Efflux and Low Permeability Barrier of the Outer Membrane in Antibacterial Activities and Inhibition of Multidrug Efflux Pumps
Synergistic Interplays between Active Drug Efflux and Low Permeability Barrier of the Outer Membrane in Antibacterial Activities and Inhibition of Multidrug Efflux Pumps
Luis Guachalla,
Arsanis Biosciences GmbH, Austria
Short Talk: Antibodies Targeting the Lipopolysaccharide O-antigen as a New Approach to Combat Multidrug Resistant Gram-negative Infections
Short Talk: Antibodies Targeting the Lipopolysaccharide O-antigen as a New Approach to Combat Multidrug Resistant Gram-negative Infections
Konstantin Taganov,
Blacksmith Medicines, USA
Short Talk: Activity of Non-Hydroxamate LpxC Inhibitors Against Acinetobacter baumannii
Short Talk: Activity of Non-Hydroxamate LpxC Inhibitors Against Acinetobacter baumannii
Coffee Break
Scott Hultgren,
Washington University School of Medicine, USA
Discovery and Development of Anti-Virulence Therapeutics against UTI Adhesins
Discovery and Development of Anti-Virulence Therapeutics against UTI Adhesins
Rahul M. Kohli,
University of Pennsylvania, USA
Short Talk: Targeting the SOS Response to Combat Antibiotic Resistance
Short Talk: Targeting the SOS Response to Combat Antibiotic Resistance
Aileen Rubio,
Pew Charitable Trusts, USA
Challenges with Animal Models in Advancing Novel Anti-Infectives
Challenges with Animal Models in Advancing Novel Anti-Infectives
17:00—19:00
Multidrug Evolutionary Strategies to Invert Resistance Selection
*
Timothy D. Read,
Emory University, USA
Session Chair
Session Chair
Pamela Yeh,
University of California, Los Angeles, USA
Higher-Order Drug Combinations and Suppressive Interactions
Higher-Order Drug Combinations and Suppressive Interactions
Gavin Barlow,
Hull and East Yorkshire Hospitals NHS Trust and University of York, UK
Treating Patients with Infections in the 21st Century - Are Antibiotic Cycling and Novel Combinations a Viable Clinical Option?
Treating Patients with Infections in the 21st Century - Are Antibiotic Cycling and Novel Combinations a Viable Clinical Option?
Karen Bush,
Indiana University, USA
Enzymatic Antimicrobial Resistance and the Search for New Inhibitors
Enzymatic Antimicrobial Resistance and the Search for New Inhibitors
Adam R. Renslo,
University of California, San Francisco, USA
Short Talk: Reversible Carbapenemase Inhibitors Bridge the Serine-Metallo Divide
Short Talk: Reversible Carbapenemase Inhibitors Bridge the Serine-Metallo Divide
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:45
Ecology and Evolution of AMR Transmission Dynamics Across Habitats
*
Michael S. Gilmore,
Harvard Medical School, USA
Session Chair
Session Chair
Gautam Dantas,
Washington University School of Medicine, USA
Networks of Exchanging Antibiotic Resistance between Commensal, Environmental and Pathogenic Bacteria
Networks of Exchanging Antibiotic Resistance between Commensal, Environmental and Pathogenic Bacteria
Ilana L. Brito,
Cornell University, USA
Horizontal Gene Transfer of Antibiotic Resistance in the Gut Microbiome
Horizontal Gene Transfer of Antibiotic Resistance in the Gut Microbiome
Brayon Fremin,
Stanford University, USA
Short Talk: Assessment of Protein Synthesis in Response to Antibiotic Treatment in the Human Gut Microbiota
Short Talk: Assessment of Protein Synthesis in Response to Antibiotic Treatment in the Human Gut Microbiota
Coffee Break
Gerry D. Wright,
McMaster University, Canada
The Resistome and Antimicrobial Discovery
The Resistome and Antimicrobial Discovery
Robert Matthew Cooper,
University of California, San Diego, USA
Short Talk: Visualizing and Predicting Horizontal Gene Transfer Enhanced by Neighbor Killing in Biofilms
Short Talk: Visualizing and Predicting Horizontal Gene Transfer Enhanced by Neighbor Killing in Biofilms
Kathryn E. Holt,
University of Melbourne, Australia
Klebsiella as a Key Trafficker of Antibiotic Resistance Genes
Klebsiella as a Key Trafficker of Antibiotic Resistance Genes
14:30—16:30
Workshop 2: Novel Strategies for AMR Discovery, Diagnostics and Modeling
*
Jennifer A. Leeds,
Novartis Institutes for BioMedical Research, USA
Session Chair
Session Chair
Allison K. Guitor,
McMaster University, Canada
In-Solution Targeted Capture of Antibiotic Resistance Genes
In-Solution Targeted Capture of Antibiotic Resistance Genes
Glen P. Carter,
University of Melbourne, Australia
The Role of Topical Antibiotics and Biocides in the Emergence of Multidrug-Resistant Staphylococcus aureus
The Role of Topical Antibiotics and Biocides in the Emergence of Multidrug-Resistant Staphylococcus aureus
Petra Éva Szili,
Biological Research Centre, Hungary
Bacterial Genome Engineering Deciphers the Evolutionary Background of Antibiotic Resistance in Clinical Pathogens
Bacterial Genome Engineering Deciphers the Evolutionary Background of Antibiotic Resistance in Clinical Pathogens
Brett E. Etchebarne,
Michigan State University, USA
Evaluation of Nucleic Acid Isothermal Amplification Methods for Human Clinical Microbial Infection and Antibiotic Resistance Gene Detection
Evaluation of Nucleic Acid Isothermal Amplification Methods for Human Clinical Microbial Infection and Antibiotic Resistance Gene Detection
Alexei Savchenko,
University of Calgary, Canada
Structural and Functional Characterization of the Environmental Antibiotic Resistome Determinants
Structural and Functional Characterization of the Environmental Antibiotic Resistome Determinants
Margot A. Zevon,
Merck, USA
Fractionation of Gram-Negative Bacteria for Direct Measurement of Compounds in Subcellular Compartments
Fractionation of Gram-Negative Bacteria for Direct Measurement of Compounds in Subcellular Compartments
17:00—18:45
Tackling AMR - Challenges in Drug Development
*
Holly Soutter,
discX, USA
Session Chair
Session Chair
Thomas F. Durand-Reville,
Entasis Therapeutics, USA
New Compound Uptake Tools to Confront the Challenges of MDR Gram-Negative Antibiotic Discovery
New Compound Uptake Tools to Confront the Challenges of MDR Gram-Negative Antibiotic Discovery
Folkert Reck,
Novartis Institutes for BioMedical Research, USA
LYS228, A Novel Monobactam to Treat Infections Caused by Multidrug-Resistant Enterobacteriaceae
LYS228, A Novel Monobactam to Treat Infections Caused by Multidrug-Resistant Enterobacteriaceae
Danica Galonic Fujimori,
University of California, San Francisco, USA
Peptidyl Transferase Center Methylation in Antibiotic Resistance
Peptidyl Transferase Center Methylation in Antibiotic Resistance
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
ACS Infectious Diseases |
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org, Phone:+1 970-262-1179 |
